Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
Would you consider lenvatinib plus everolimus as first line treatment for a patient with tuberous sclerosis and metastatic renal cell carcinoma?
Related Questions
For patients who progress to mCRPC on ADT+ARSI started in mCSPC setting, do you continue the ARSI if patients have had a mixed response?
How would you approach treating a patient with prostate adenocarcinoma with urothelial features?
For patients with T1 bladder cancer who have severe obstructive uropathy/hydronephrosis, do you treat as high risk stage I disease with RC, or clinically upstage and manage as a more locally advanced disease (NAC+RC)?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
Would you consider maintenance immunotherapy after cisplatin-gemcitabine chemotherapy and chemoRT for stage 3 bladder cancer in a patient declining cystectomy or who is a poor surgical candidate?
How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?
Would you recommend neoadjuvant chemotherapy for a 3.5 cm low-grade UTUC in a cisplatin-eligible patient?
What additional evaluation or surveillance would you recommend for a patient with a persistently elevated PSA > 50 but repeatedly negative biopsies, MRI, and PSMA PET?
Do you routinely do restaging imaging before surgery for a patient who completed neoadjuvant treatment for MIBC?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?